Evolent Health, Inc. (EVH) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2025. Evolent Health, Inc. is a market leader in connecting care for patients with complex conditions (oncology, cardiology, musculoskeletal) through value-based care solutions. The company operates as a holding company with one reportable segment. During 2025, the company sold its Evolent Care Partners (ECP) subsidiary for $100 million (subject to adjustments) and exchanged its Series A Preferred Stock for a Second Lien Term Loan Facility.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $1,876.2 million | $2,554.7 million | (26.6%) |
| Operating Loss | $(410.1) million | $(40.5) million | (913.1%) |
| Net Loss (Common Shareholders) | $(579.4) million | $(93.5) million | N/A |
| Cost of Revenue | $1,476.3 million | $2,187.4 million | (32.5%) |
| Medical Expense Ratio (MER) | 80.5% | 82.3% | Improved |
| Cash & Cash Equivalents | $151.9 million | $104.2 million | +45.8% |
| Restricted Cash | $28.8 million | $74.3 million | (61.2%) |
| Total Debt (Principal) | $934.0 million | N/A | N/A |
Note: The significant increase in operating loss is primarily driven by a non-cash goodwill impairment charge of $398.0 million.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by $678.5 million (26.6%). This was primarily due to contractual updates with Performance Suite customers, including a $447.3 million transition of a customer to the Specialty Technology and Services Suite and a $267.4 million reduction in scope for other customers. These changes were accompanied by significant reductions in medical claims expense.
- Goodwill Impairment: Due to a prolonged decline in stock price (from $23.35 in Oct 2024 to $6.67 in Oct 2025), the company recorded a $398.0 million non-cash, non-tax-deductible goodwill impairment charge.
- Disposal of ECP: The company sold Evolent Care Partners for net proceeds of $91.3 million, recognizing a gain of $14.9 million.
- Debt Restructuring: The company issued $166.8 million in 2031 Notes to repurchase $167.4 million of 2025 Notes. Additionally, Series A Preferred Stock was exchanged for a $175.0 million Second Lien Term Loan.
- Medical Costs: Total claims incurred decreased by $575.7 million to $907.3 million, driven by the scope reductions mentioned above, despite industry-wide cost pressures.
Guidance, Outlook, and Risks
Management Commentary: Management notes that medical claims costs in the Performance Suite grew faster than historical norms in 2024 and continued to do so in 2025, driven by higher disease prevalence and cost per active patient. The company expects these industry-wide trends to continue impacting financial results.
Regulatory Environment: The enactment of the "One Big Beautiful Bill Act" (OBBBA) in July 2025 introduced changes to Medicaid, Medicare, and ACA Health Exchanges, including stricter eligibility criteria. Management is evaluating the impact, which could result in reduced membership and material adverse effects on the business.
Key Risks:
- Customer Concentration: The top four partners (Molina, Cook County, Florida Blue, Centene) represented 68.5% of 2025 revenue. Loss of any significant partner would materially impact results.
- Performance-Based Risk: The company assumes financial risk for medical claims under capitation arrangements. Inaccurate predictions of exposure or rising medical costs (e.g., oncology) can negatively impact profitability.
- Legal Proceedings: The company received a Civil Investigative Demand (CID) from the DOJ in August 2025 regarding a False Claims Act investigation involving a former customer (no longer a client since 2021). The outcome and potential loss are currently indeterminable.
- Liquidity: While the company believes current cash is sufficient for the next 12 months, it faces significant debt service obligations and potential future payments under a Tax Receivables Agreement (TRA) totaling $108.9 million.
Investor Verification Checklist
- Goodwill Impairment Assumptions: Verify the discounted cash flow assumptions (revenue growth, margins, discount rate) used to justify the $398 million impairment charge.
- Medical Expense Ratio (MER) Trends: Monitor the MER for the Performance Suite, excluding the impact of the ECP sale, to assess the sustainability of cost management amidst rising industry medical trends.
- Customer Contract Renewals: Track the status of contracts with the top four partners, particularly Molina Healthcare (25.7% of revenue), given the recent history of scope reductions and renegotiations.
- DOJ Investigation Status: Monitor updates regarding the False Claims Act investigation initiated in August 2025 to assess potential liability exposure.
- Debt Covenants: Review compliance with financial covenants in the Credit Agreements, specifically the minimum liquidity test and total secured leverage test, given the high debt load ($934 million principal).
- OBBBA Impact: Assess the specific impact of the new federal legislation on Medicaid and Medicare membership numbers for the company's partners.